Q4 2023

Filed Feb 27, 2024 · 10-K · 58 days after period end · 0001590750-24-000007

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue

$72.00K

derived−31.4% vs Q4 2022

Net Income

-$66.86M

derivedN/M vs Q4 2022

EPS, diluted—

Same quarter

Metric	Q4 2023derived from reported figures	Q4 2022derived from reported figures	Q4 2021derived from reported figures	Q4 2020derived from reported figures
Revenue	$72.00K	$105.00K	$214.00K	$54.00K
Net Income	-$66.86M	-$45.79M	-$28.95M	-$90.74M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR